The increasing use of direct oral anticoagulants (DOACs) has transformed the prevention and treatment of thromboembolic disease. However, managing life-threatening bleeding in anticoagulated patients remains a critical clinical challenge. Familiarity with specific reversal agents is essential for timely and effective emergency management. Here is a quick question on anticoagulant reversal strategies! (Scroll down to answer the question) ##Reference## Pollack, C. V., Jr., Reilly, P. A., van Ryn, J., Eikelboom, J. W., Glund, S., Bernstein, R. A., Dubiel, R., Huisman, M. V., Hylek, E. M., Kam, C.-W., Kamphuisen, P.
W., Kreuzer, J., Levy, J. H., Royle, G., Sellke, F. W., Stangier, J., Steiner, T., Verhamme, P., Wang, B., . . . Weitz, J. I. (2017). Idarucizumab for dabigatran reversal — full cohort analysis. New England Journal of Medicine, 377(5), 431–441.## ##Disclaimer## The content…
